This contrasts with prior studies indicating a combined adverse effect of these alterations on prognoses [9], suggesting a need for further investigation into how EGFR amplification and EGFRvIII mutations interacted with other molecular and clinical factors, such as the tumor microenvironment and therapy resistance. This evidence concerns the gene EGFR and neoplasm.